Xcellon Biologics, a U.S.-based Contract Research, Development and Manufacturing Organization (CRDMO) specializing in bioconjugates and complex biologics, announced that it has signed a definitive agreement to acquire the GMP biologics manufacturing facility from NextCure, Inc. The acquisition marks a transformational milestone in the company’s evolution, establishing Xcellon as an end-to-end CRDMO with integrated capabilities spanning discovery through clinical supply.
As part of its next phase of growth, Xcellon Biologics appointed co-founder Abhishake Chhibber as Chief Executive Officer to lead the company’s transformation into an end-to-end CRDMO for bioconjugates and complex biologics.
“This acquisition represents far more than the expansion of our manufacturing capabilities,” said Abhishake Chhibber, Chief Executive Officer of Xcellon Biologics. “It represents the next chapter in our vision to build one of the nation’s premier CRDMOs for bioconjugates and complex biologics. By integrating antibody development, bioconjugation development, analytical sciences, and GMP manufacturing within a single organization, we are creating a platform that enables innovators to move seamlessly from discovery through clinical supply. We believe this integrated approach will help accelerate the development of breakthrough therapies while strengthening the U.S. biomanufacturing ecosystem.”
“The acquisition significantly accelerates our ability to support biotechnology innovators,” said Yuk Chiu, Chief Operating Officer of Xcellon Biologics. “By reducing handoffs between service providers and maintaining scientific continuity throughout development, we help clients advance complex biologics more efficiently while maintaining operational excellence and the flexibility required for today’s innovative therapeutic programs.”